
Accomplished specialty sales representative and registered nurse with over 15 years of combined clinical, sales, and healthcare leadership experience. Proven track record of successful product launches, consistently achieving top-tier performance and earning multiple regional and national sales awards. Deep clinical expertise and established physician relationships leveraged to drive the adoption of complex specialty therapies. Eager to contribute extensive background to an internal AbbVie launch role for an emerging Parkinson's medication.
Joined AbbVie mid-launch of Ubrelvy (ubrogepant) during the COVID-19 pandemic, simultaneously promoting Vraylar (cariprazine) across psychiatry and neurology accounts before transitioning fully to the migraine portfolio with the subsequent launch of Qulipta (atogepant).
Vraylar (cariprazine) – Psychiatry | July 2020 – Mid-2021
• Co-promoted Vraylar alongside Ubrelvy to psychiatrists, neurologists, and primary care providers as an atypical antipsychotic for schizophrenia and bipolar disorder, building foundational relationships across a broad specialty call universe.
• Established key account relationships with high-prescribing psychiatry practices that provided a strong foundation for subsequent neurology-focused growth.
Ubrelvy (ubrogepant) & Qulipta (atogepant) – Migraine | July 2020 – Present
• Rapidly built neurology territory mid-launch of Ubrelvy under pandemic conditions, establishing strong relationships with neurologists, headache specialists, and primary care providers.
• Led Qulipta launch in territory, positioning it as a first-in-class daily oral CGRP antagonist for migraine prevention, resulting in sustained prescription growth.
• Cultivated a high-value network of key influencers and specialty physicians to accelerate brand adoption and support peer-to-peer education initiatives.
• Delivered educational in-services and speaker event coordination to reinforce clinical messaging across a complex specialty marketplace.
• Leveraged nursing background to translate complex pharmacology and approved mechanism-of-action data into actionable clinical insights for healthcare providers.
• Consistently exceeded quarterly and annual revenue targets throughout a high volume territory, earning national and regional recognition across multiple years.